Axinn Successfully Advocates for Preservation of 180-Day Marketing Exclusivity for Carvedilol ER
April 13, 2018
Axinn successfully advocated that FDA should preserve the 180-day marketing exclusivity period relating to a generic version of SmithKline’s Coreg CR (carvedilol phosphate extended-release capsules) even though it took the ANDA applicant over 10 years to obtain tentative approval of its product. Through a series of correspondence submitted to FDA over the course of a number of years, Axinn successfully convinced FDA that the 180-day exclusivity period was not forfeited by Mutual Pharmaceutical Company (now Sun Pharma) because of a change in the approval requirements for the product.
Click here to read FDA's decision and here to read press coverage on FDA Law Blog.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Antitrust 101: Criminal Antitrust Enforcement in U.S. v. US Gypsum Co., 438 US 422 (1978)
Podcast
FTC Peeling Back the Layers of the Orange Book
Axinn Viewpoints
Intellectual Property
Patman Returns … and Retreats Again
Axinn Viewpoints
Antitrust
Axinn Successfully Reunites One of Its Pro Bono Clients, a Former Afghan Army Captain, with His Wife and Four Children
Pro Bono
The Texas v. Blackrock ESG Case: The FTC and DOJ Have Entered the Chat
Axinn Viewpoints
Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025
Sponsorship
Antitrust